Parathyroid cancer as rare cause of primary hyperparathyroidism. Case report and review of the literature by Troilo, Vito Leopoldo et al.




A single glandular adenoma or hyperplasia are the
most frequent cause of primary hyperparathyroidism
(PHPT). It is rarely caused by hyperfunctioning carci-
noma, that accounts for 0.5% up to 5% of the patients
with PHPT. A pre-operative diagnosis is difficult, and
many features of malignacy are discussed. The first ca-
se was described over 60 years ago, but because of its
rarity is difficult to estabilish clinical, histopathologi-
cal and radiologic criteria of malignancy. Most of PC
are hyperfunctioning, with marked serum PTH levels;
a palpable mass also suggest malignancy. Surgical ap-
proach of PC is the gold standard treatment, with en
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Primary hyperparathyroidism (PHPT) due to parathiroid carcinoma
is rare, and affects more frequently women in their 4th-5th decades of
life. Parathyroid cancer (PC) accounts for 0.5% up to 5% of the pa-
tients with primary hyperparathyroidism (PHPT). Diagnosis of PC is
not easy, and a lot of patients with PHPT receive no pre-operative or
intra-operative diagnosis of malignancy. Most of PC are hyperfunctio-
ning, with marked serum PTH levels, and symptoms occurs more fre-
quently than in benign disease. We report the case of a 52 years old wo-
man that underwent a single parathyroidectomy for hyperfunctioning
gland. Histological examination revealed carcinoma. 
Parathyroid carcinoma is rare and surgery represent the only cura-
tive approach, although there can be a local reccurence of the disease. A
pre-operative diagnosis is not easy, and many features that suggest the
diagnosis of malignancy are controversial. According to the literature,
we think that the cure of the parathyroid cancer is difficult to achieve. 
After two years of follow- up, our patient is in good conditions and
has no evidence of disease. A careful follow up is of primary importan-
ce to diagnose the local recurrence of disease and perform a second sur-
gical  treatment, to achieve the control of hypercalcemia, which causes
severe metabolic alterations and visceral lesions until the death.
RIASSUNTO: Carcinoma paratiroideo: una causa rara di iper-
paratiroidismo primario. Caso clinico e revisione della letteratura.
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L’iperparatiroidismo primario raramente è causato da un carcino-
ma della paratiroide, che colpisce più frequentemente le donne nella 4ª-
5ª decade di vita. Il carcinoma delle paratiroidi si riscontra infatti nel-
lo 0.5% fino al 5% dei pazienti con iperparatiroidismo primario. La
diagnosi di carcinoma non è semplice, e in molti pazienti con  iperpa-
ratiroidismo primario non è possibile nè pre-, nè intra-operatoriamen-
te. Molti carcinomi paratiroidei sono iperfunzionanti, con elevati livelli
ematici di paratormone, e quindi sintomatici più frequentemente rispetto
alle forme benigne. Riportiamo il caso di una donna di 52 anni sotto-
posta a paratiroidectomia della unica ghiandola iperfunzionante, in cui
l’esame istologico ha rivelato un carcinoma. 
In questi casi la chirurgia rappresenta l’unica terapia efficace, an-
che se è frequente una ripresa locale di malattia. La diagnosi pre-ope-
ratoria non è semplice e molti elementi che ne suggeriscono la malignità
sono controversi. In accordo con quanto riportato in letteratura, rite-
niamo che la guarigione definitiva del carcinoma delle paratiroidi sia
difficilmente conseguibile. 
Dopo due anni di follow-up la nostra paziente è in buone condi-
zioni generali e libera da malattia. Un accurato follow-up è di fonda-
mentale importanza per una diagnosi tempestiva di ripresa di malat-
tia e per attuare un reintervento con il fine di ottenere il controllo del-
l’ipercalcemia che può essere causa di complicanze anche letali.
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bloc resection of pathologic parathyroid gland, ipsila-
teral thyroid lobe and muscles. 
Local recurrence occurs in up to 30%, in the pri-
mary site rather than in distant ones, and can be trea-
ted with a palliative surgical reexploration.
Chemotherapy and radiotherapy ore not able to con-
trol local recurrence or distant metastases.
Case report
Clinical features and diagnostic work-up
A 52 years-old female was referred to us in October 2006 with
a diagnosis of primary hyperparathyroidism (PHPT) and a single
parathyroid gland mass, suspicious for adenoma. The patient com-
plained of profound asthenia at the legs over the past 2 years. About
3 months before, she had suffered of dysphonia and sense of ob-
struction in the throat, bone pain and demineralization. 
Ultrasonography of the neck showed an asymmetry of the thy-
roid gland with marked prevalence of the right lobe, and disho-
mogeneous structure. Close to the upper third of the right lobe
there was an hypoecogenous nodule, with regular and clear bor-
ders, sized of 28x16 mm. Ecocolor-Doppler fluximetry showed wi-
despread intensity of blood flux around and inside the nodule (Pat-
tern III). Also there were other little thyroid nodules. A fine need-
le agobiopsy (FNAB) was made on this nodule, with result C3 (stri-
pes and microcytoincluded of microfollicular nodule with ani-
sokariosis and solid-trabecular architectural pattern). Immuno-
chemistry reaction was focally positive for galectyn 3. Laboratory
tests showed marked hypercalcemia (13.5 mg%, range 8.6-10.3),
hypophosphoremia (2.3 mg%, range 2.6-4.5), hypercalciuria (359
mg/24h, range 50-250), elevated serum Parathormone (PTH)
(2039 pg/mL, range 9-70). MRI scan of the neck, showed a no-
dular image of diameter 4 cm, with clear borders and dishomoge-
neous signal intensiy and enhancement, close to the right lobe of
the thyroid gland (Fig. 1). Clinical diagnosis was of primary hy-
perparathyroidism maybe caused by parathyroid hyperfunctioning
adenoma.
At admission, laboratory tests were repeated, confirming hy-
percalcemia (13.9 mg/dL, range 8.05-10.1), hypophosphoremia (1.9
mg/dl, range 2.5-4.9), elevated blood levels of PTH (798 pg/mL,
range 6.4-52) and serum alkaline phosphatase levels (803u/L, ran-
ge 50-136). Blood levels of thyroid hormones were normal. At phy-
sical examination a palpable mass in the right side of the neck was
evident, and dysphonia was also perceptible.
A laryngoscopic exam revealed lower motility of the right vo-
cal cord. Endocrinologic evaluation confirmed the diagnosis of
PHPT. To make clear on the thyroid and parathyroid disease, a
scintigraphy with 99mTc-Sestamibi (740 MBq) and 99mTcO4 (110
MBq) was made. The result was that thyroid gland was normal
for site, size and symmetry of the lobes. Scintigraphy with 99mTc-
Sestamibi showed a fixation area in the upper third of the right
lobe after 20 min.; after 2 hours this fixation area persisted in the
same site. The digital removal image confirmed the presence of
selective fixation of the lipofilic cation in the upper third of the
right thyroid lobe (Fig. 2). The scintigraphic diagnosis was of hy-
perfunctioning right upper parathyroid gland. The right upper pa-
rathyroid excision was the treatment of choice. Clinical and pre-
operative conditions of the patient were good, and anesthesiolo-
gical risk was ASA II.
Surgical treatment
With the patient in supine position and extended neck, a Ko-
cher incision was made. At a first examination, behind the thyroid
right lobe there was a parathyroid mass. After a careful dissection,
an avascular split layer was found between thyroid and upper pa-
rathyroid, that was easily isolated. This gland was brownish and in-
creased in consistence. The lower right parathyroid, appeared nor-
mal. The right thyroid lobe was thin, compressed by the enlarged
parathyroid. After laryngeal recurrent nerve identification, the ri-
ght upper parathyroidectomy was performed.
Post-operative outcome was regular. In the 1st post-operative day,
Fig. 1 - MRI scan: a nodular image of diameter 4 cm, with clear borders and dishomogeneous signal intensiy and enhancement, next to the right lobe of the thy-
roid gland.
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blood level of parathormone resulted in 6.4 pg/mL (range 6.4-52);
calcemia was 9.5mg/dL (range 8-10.5). Although normal values of
calcemia, the patient had hypocalcemic crisis with swarming and
tetanic contraction of the hands, quickly resolved with e.v. calcium
gluconate; then, we decided to give oral calcium (1 g/tid) and cal-
citriol (0.25mcg/bid) even with normal calcemia, until the symp-
toms were resolved. These symptoms became slighter and slighter,
until disappearing after 10 days.    
An endocrinologic evaluation was repeated, and these unex-
pected symptoms were attributed to the “hungry bone syndrome”.
The only therapy was oral administration of calcium until symp-
tom’s complete resolution. The day after parathyroidectomy, the voi-
ce improved.
The patient was discharged in good conditions, and got oral
administration of calcium and calcitriol, step by step reduced, ba-
sed on level of calcemia.
Pathology
At histological grossly examination, the nodule appeared yel-
low-brownish, weight 5,00 grams, diameters 28x20x15 mm. At sec-
tion, there were two white-greyish areas, with vanished borders, dia-
meters 15 and 13 mm..
The diagnosis after microscopic examination was of chief cel-
ls parathyroid carcinoma, with endovascular permeation; resection
margins were clear from disease. Immuno-hystochemistry tests re-
vealed positiveness of the neoplastic cells for parathormone.
Follow-up
After 3 months, the patient underwent an ultrasonography of
the neck, which revealed hyperecogenous signal behind the right
thyroid lobe, referable to cicatricial results, and no pathologic la-
terocervical lymphnodes. PTH blood level was high, 101 pg/mL
(range 6.4-52). Then, the patient underwent a scintigraphy with
99mTc-Sestamibi (370 MBq) and 99mTcO4 (148 MBq), which re-
vealed an hypofunctional right thyroid lobe referable to cicatricial
results, and the absence of hyperfunctioning parathyroid tissue. Voi-
ce quickly improved by logopedic exercises. After 6 months PTH
levels were normal, as ultrasonography too. 
A careful follow-up was performed every three months. After
2 years, the patient is in good conditions and laboratory tests con-
tinue to reveal normal values of serum PTH. Ultrasonographic exa-
mination of the neck is normal too, without recurrence of disease
and pathologic laterocervical lymph nodes. The patient get oral ad-
ministration of levotiroxin 50 mcg/die because of hypofunctioning
thyroid nodules.
Discussion
Primary hyperparathyroidism (PHPT) is frequently
caused by a single adenoma or hyperplasia, rarely by car-
cinoma, and affects more frequently women in their 4th
- 5th decades of life (1). Parathyroid cancer (PC) is a ra-
re endocrine malignancy, commonly hyperfunctioning,
accounting for 0.5% up to 5% of the patients with pri-
mary hyperparathyroidism (PHPT) (2). Diagnosis of PC
is not easy, infact 86% of the patients with PHPT re-
ceive no pre-operative or intra-operative diagnosis of ma-
lignancy (3, 4). There are no sexual differences in pa-
tients with PC, despite the female predominance of be-
nign PHPT, but patients with PC are 10 years younger
than those with benign PHPT. Most of PC are hyper-
functiong, with marked serum PTH levels, and symp-
toms occurs more frequently than in benign disease (5). 
The first case was described by Armstrong over 60
years ago (6), but because of its rarity, although there
are many studies which try to estabilish clinical, histo-
pathological and radiologic criteria of malignancy, pre-
operative diagnosis of PC is difficult. The  results of the-
se studies are doubtful and not always useful to allow
an accurate pre-operative diagnosis of PC. 
Surgical approach of PC is the current gold standard
treatment, with en bloc resection of parathyroid gland,
ipsilateral thyroid lobe and muscles. Histological featu-
res for malignancy were proposed by Schantz and Ca-
stleman (7) (Tab. 1): local invasion of contigous struc-
tures, nodal or distant metastases, capsular or vascular
invasion, fibrous trabeculae, high mitotic pattern. 
Clinical findings for pre-operative suspicious of PC
are: laryngeal recurrent nerve palsy, palpable mass, tu-
mor size>3cm, calcium>14mg/dL, severe hyperpa-
rathyroidism, elevated levels of alkaline phosphatise (6).
Intra-operative findings for malignancy are: local infil-
tration, greyish color, firm mass. Pre-operative imaging
Fig. 2 - A fixation area of the lipofilic cation in the upper third of the right thyroid lobe.
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study with ultrasonography, Tc99m-sestamibi scintigraphy
and CT scan can’t make differential diagnosis between
benign disease or malignancy. Tc99m-sestamibi scinti-
graphy is the most sensitive imaging modality used for
localizing abnormal parathyroid tissue, with an accuracy
of 90% (5). Sestamibi is a lipophilic cation that accu-
mulates almost exclusively in the mitochondria; the
oxyphil cells have an intensely eosinophilic cytoplasm
rich of mitochondria. Principal cells are the active en-
docrine cells, with slight eosinophilic cytoplasm con-
taining few mitochondria. A positive sestamibi scan is
more frequent in adenomas rich in oxyphil cells than in
predominance of chief cells (8). In absence of metasta-
tic disease, it is difficult to establish a pre-operative dia-
gnosis of PC. Agarwal et al. (9) examined prospectively
100 patients with PHPT, finding only 4 cases of PC. Cli-
nical, biochemical, radiological and pathological featu-
res were examined, but there were no significantly dif-
ferences among adenoma, hyperplasia and carcinoma.
Only the tumor/PTG (parathyroid total gland) weight
(mg) in patients with carcinoma (15,080 ± 5,638) was
significantly higher when compared with adenoma
(5,724 ± 1,257) and hyperplasia (3,310 ± 0,655)
(P=0.002). 
Even if histological patterns were established by
Schantz and Castleman (7), it is often difficult to make
diagnosis of PC only on the basis of histology; infact,
one of these findings can be seen in adenomas, but the
presence of several findings in the same histological pic-
ture increase the possibility of malignancy (10). Lang and
Lo (5) reviewed the literature on parathyroid cancer. The
clinical presentation with symptoms of hypercalcemia,
including anorexia, weight loss, fatigue, weakness, nau-
sea, vomiting, bone pain, polyuria and polydipsia, com-
plications such as pathologic fracture, renal colic, acu-
te pancreatitis, peptic ulcer, occur more frequently than
in benign disease. A palpable neck mass is present in up
to 50% of PC; hoarseness of voice due to recurrent laryn-
geal nerve palsy increase the possibility of malignancy;
cervical lymph node metastases are present in 15-20%
of cases. Besides, pre-operative PTH level and gland wei-
ght seems to be predictive factors of malignancy. Howe-
ver, up to 30% of cancers haven’t these characteristic fea-
tures and benign disease can be similar to malignancy;
then, a definitive diagnosis based on clinical or bioche-
mical criteria is virtually impossible.
In view of the complexities about the diagnosis of PC,
the most reliable way of diagnosing it is the demonstra-
tion of contiguous invasion or distant and lymphnodal
metastases (9). In a retrospective analysis of 168 patients
treated surgically for PHPT, Chang et al. (6) found 8 ca-
ses of PC. The mean age was 58.1 years (range 36-82
years), a mean calcium level of 11.57mg/dL and a mean
PTH level of 623 pg/dL (88-2095 pg/dL). All 8 cases
were hyperfunctioning PC but none had symptoms of
hypercalcemia, and only in 25% (2 cases) a palpable mass
was present. Although all eight patients underwent ul-
trasonography and sestamibi scan, none was suspicious
for PC. At histological examination, all the PC presen-
ted at least two histological criteria for malignancy, and
a mean size of 2.18 cm, lower than the one proposed for
malignancy; all cases had signs of vascular or capsular in-
vasion and mitotic pattern was high in 50%. 
PC should be considered for differential diagnosis in
asymptomatic PHPT, but the absence of severe hyper-
calcemia and symptoms should not rule out PC. Intra-
operative frozen section with finding of high mitotic pat-
tern will suggest the diagnosis, but surgical examination
is very important for a radical or conservative treatment.
Local recurrence occurs in up to 30%, in the primary
site rather than in distant ones, but can be treated with
a palliative surgical reexploration. However, Cohn et al.
(11) demonstred that not all patients need a prophylactic
radical neck dissection, because there is no improvement
in survival rate and morbidity. Hundahl et al. (4) de-
monstrated that in 286 cases of PC, only 15.2% of the
patients that underwent lymph nodes dissection had me-
tastases at the first excision, while 32% had metastases
at reexploration; than, lymphnodal dissection is re-
commended only in cases of evident lymphnodal me-
tastases. Pelizzo et al. (2) also confirmed a low rate of
lymphnodal metastases at first surgery and reexploration. 
A new challenge is the genetic screening; there isn’t
a specific gene involved in the cancerogenesis of PC, but
in sporadic cases of PC there is mutation of HRPT2 ge-
ne(12). About the follow-up, for hyperfunctioning PC
biochemical markers (S-Ca, PTH) are more important
than image techniques (ultrasonography, Scintigraphy,
CT scan) (2, 5). Survival rate at 5 and 10 years is va-
riable, 35-85.5% (2, 13). Chemotherapy and radiothe-
rapy ore not able to control local recurrence or distant
metastases (2, 5).
Conclusions
We reported this case of parathyroid cancer becau-
se it’s a rare neoplasm and because as described by other
authors we had some difficulties to make diagnosis of
malignancy. According to the literature, we think that
the cure of the parathyroid cancer is difficult to achie-
TABLE 1 - HISTOLOGICAL FEATURES OF MALIGNANCY
OF PARATHYROID MASS.
Local invasion of contigous structures
Nodal or distant metastases
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ve. After two years of follow up the patient is in good
conditions and has no evidence of disease. Besides, re-
currence is the natural cancer history. 
The aim of our careful follow up is to diagnose the
local recurrence of disease so that we can perform a se-
cond surgical  treatment, to achieve, the control of the
hypercalcemia, which causes following diseases and
death.
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